Technical Analysis for ZBIO - Zenas BioPharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Gapped Up | Strength | -0.58% | |
| Up 3 Days in a Row | Strength | -0.58% | |
| Up 4 Days in a Row | Strength | -0.58% | |
| Gapped Up | Strength | -0.05% | |
| Up 3 Days in a Row | Strength | -0.05% | |
| Pocket Pivot | Bullish Swing Setup | 0.92% | |
| Hot IPO Pullback | Bullish Swing Setup | 9.74% | |
| NR7 | Range Contraction | 9.74% | |
| New 52 Week Low | Weakness | 9.74% | |
| New 52 Week Closing Low | Bearish | 10.52% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 16 hours ago |
| Down 2 % | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
| Possible Inside Day | about 17 hours ago |
| Up 5% | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
Zenas BioPharma, Inc. Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Immune System Antibodies Monoclonal Antibody Multiple Sclerosis Glycoproteins Systemic Lupus Erythematosus Immunoglobulin E Warm Autoimmune Hemolytic Anemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.5 |
| 52 Week Low | 16.17 |
| Average Volume | 136,449 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 18.08 |
| Average True Range | 1.52 |
| RSI (14) | 47.37 |
| ADX | 0.0 |
| +DI | 21.72 |
| -DI | 9.72 |
| Chandelier Exit (Long, 3 ATRs) | 15.94 |
| Chandelier Exit (Short, 3 ATRs) | 20.73 |
| Upper Bollinger Bands | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.13 |
| MACD Signal Line | 0.02 |
| MACD Histogram | 0.1138 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.64 | ||||
| Resistance 3 (R3) | 20.77 | 20.26 | 20.31 | ||
| Resistance 2 (R2) | 20.26 | 19.77 | 20.19 | 20.20 | |
| Resistance 1 (R1) | 19.48 | 19.46 | 19.87 | 19.35 | 20.10 |
| Pivot Point | 18.97 | 18.97 | 19.17 | 18.90 | 18.97 |
| Support 1 (S1) | 18.19 | 18.48 | 18.58 | 18.06 | 17.30 |
| Support 2 (S2) | 17.68 | 18.17 | 17.61 | 17.20 | |
| Support 3 (S3) | 16.90 | 17.68 | 17.09 | ||
| Support 4 (S4) | 16.77 |
